UNIGE document Scientific Article
previous document  unige:77344  next document
add to browser collection

How to manage prasugrel and ticagrelor in daily practice

Published in European Journal of Internal Medicine. 2014, vol. 25, no. 3, p. 213-220
Abstract Prasugrel and ticagrelor are next-generation antiplatelet agents that provide a rapider and more potent inhibition of platelet P2Y12 receptor than clopidogrel. In combination with aspirin, these new P2Y12 inhibitors are now the first line treatments for patients with acute coronary syndrome. However, these potent antiplatelet agents introduce a new paradigm in the daily management of antithrombotic drugs, particularly when an invasive procedure is planned. The pharmacology of these antiplatelet agents, and the results of the main clinical trials, are reviewed with a special focus on good prescription practices (indications, contra-indications, drug interactions), and on peri-operative management. Strategies are proposed for safely reducing the bleeding risk in elderly patients, in patients requiring concomitant oral anticoagulant therapy, or in patients with an increased haemorrhagic risk.
Keywords Adenosine/analogs & derivatives/therapeutic useHumansPiperazines/therapeutic usePlatelet Aggregation Inhibitors/therapeutic usePostoperative CarePostoperative Hemorrhage/chemically induced/prevention & controlPractice Guidelines as TopicPreoperative CarePurinergic P2Y Receptor Antagonists/therapeutic useRisk FactorsThiophenes/therapeutic use
PMID: 24529662
Full text
Article (Published version) (464 Kb) - public document Free access
Research group Geneva Platelet Group (13)
(ISO format)
BONHOMME, Fanny, FONTANA, Pierre, RENY, Jean-Luc. How to manage prasugrel and ticagrelor in daily practice. In: European Journal of Internal Medicine, 2014, vol. 25, n° 3, p. 213-220. doi: 10.1016/j.ejim.2014.01.016 https://archive-ouverte.unige.ch/unige:77344

279 hits



Deposited on : 2015-11-18

Export document
Format :
Citation style :